Von Willebrand Disease: Bridging the Evidence Gap with a Call to Action for Equitable Care
Nathan Connell, Hematologist at Harvard Medical School, shared a post on LinkedIn:
“Thank you to Drs. Kelsey Uminski, Paula James, and Roy Khalife for asking me to join them in preparing this commentary in Haemophilia Journal, “Bridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence-Based Care.”
For decades, von Willebrand disease (VWD), the most common inherited bleeding disorder, has been under-researched compared to hemophilia. This evidence gap has led to significant challenges in patient care, including clinical uncertainties and wide variability in practice. This paper outlines why this gap exists and presents a coordinated, five-point research agenda to help close it:
▪️Patient-Centered Trial Design: Shifting away from endpoints that don’t capture the full impact of VWD and focusing on what matters most to patients, like the effect on quality of life.
▪️Adoption of Core Outcome Sets: Standardizing key outcomes to make research more comparable and clinically applicable.
▪️PK-Guided Therapy: Developing accessible tools for individualized, precise dosing, similar to what has revolutionized hemophilia care.
▪️Network Research and Real-World Data: Expanding registries and networks to gather data and better understand long-term outcomes for patients.
▪️Embedded Patient and Clinician Partnerships: Meaningfully engaging with patients and providers to ensure research questions are relevant to real-world needs.
This call to action is about more than just science; it’s about equity. VWD has suffered from historical underinvestment and under recognition, especially for conditions that disproportionately affect women. We believe equitable care requires equitable evidence, and VWD is too important to overlook.
Read the full commentary here.”

More posts featured in Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES